U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30N2O4S2
Molecular Weight 438.604
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIBAMPATOR

SMILES

CC(C)S(=O)(=O)NC[C@H](C)C1=CC=C(C=C1)C2=CC=C(CCNS(C)(=O)=O)C=C2

InChI

InChIKey=ULRDYYKSPCRXAJ-KRWDZBQOSA-N
InChI=1S/C21H30N2O4S2/c1-16(2)29(26,27)23-15-17(3)19-9-11-21(12-10-19)20-7-5-18(6-8-20)13-14-22-28(4,24)25/h5-12,16-17,22-23H,13-15H2,1-4H3/t17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H30N2O4S2
Molecular Weight 438.604
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including

Mibampator, also known as LY451395, is a potent and highly selective an AMPA receptor potentiator, which plays a role in the regulation of the glutamatergic system. The AMPA system also has important functions in the regulation of synapses, synaptic regeneration, and neuroprotection and is therefore a good therapeutic target for treatments aiming to improve cognition and function or alter disease progression. Mibampator was in the phase II clinical trial for the treatment of agitation and aggression in Alzheimer's disease (AD).

Originator

Curator's Comment: # Lilly Research Laboratories, Eli Lilly and Company

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.082 ng/mL
5 μg single, oral
dose: 5 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIBAMPATOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
219 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIBAMPATOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.39 h
5 μg single, oral
dose: 5 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIBAMPATOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.8 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MIBAMPATOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg 2 times / day multiple, oral (unknown)
Studied dose
Dose: 3 mg, 2 times / day
Route: oral
Route: multiple
Dose: 3 mg, 2 times / day
Sources:
unhealthy
n = 63
Health Status: unhealthy
Condition: aggression
Sex: M+F
Food Status: UNKNOWN
Population Size: 63
Sources:
PubMed

PubMed

TitleDatePubMed
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.
2013 May
Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies.
2013 May
Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies - ADDENDUM.
2014 Jul 3
Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
2015
Patents

Sample Use Guides

3 mg BID oral 12 weeks. May be reduced to 1 mg if unable to tolerate
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:14:54 GMT 2023
Edited
by admin
on Fri Dec 15 18:14:54 GMT 2023
Record UNII
A9V5BW73UU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIBAMPATOR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
mibampator [INN]
Common Name English
LY451395
Code English
N-((2R)-2-(4'-(2-((METHYLSULFONYL)AMINO)ETHYL)BIPHENYL-4-YL)PROPYL)PROPANE-2-SULFONAMIDE
Systematic Name English
LY 451395
Code English
LY-451395
Code English
MIBAMPATOR [USAN]
Common Name English
2-PROPANESULFONAMIDE, N-((2R)-2-(4'-(2-((METHYLSULFONYL)AMINO)ETHYL)(1,1'-BIPHENYL)-4-YL)PROPYL)-
Systematic Name English
((2R)-2-(4-(4-(2-((METHYLSULFONYL)AMINO)ETHYL)PHENYL)PHENYL)PROPYL)((1-METHYLETHYL)SULFONYL)AMINE
Systematic Name English
Mibampator [WHO-DD]
Common Name English
Code System Code Type Description
SMS_ID
300000034286
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
FDA UNII
A9V5BW73UU
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
WIKIPEDIA
Mibampator
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
CAS
375345-95-2
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
USAN
WW-70
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
NCI_THESAURUS
C174617
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
DRUG BANK
DB12717
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
INN
9260
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID20190977
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL1277001
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
PUBCHEM
9889366
Created by admin on Fri Dec 15 18:14:54 GMT 2023 , Edited by admin on Fri Dec 15 18:14:54 GMT 2023
PRIMARY
Related Record Type Details
TARGET->POSITIVE ALLOSTERIC MODULATOR (PAM)
High-impact AMPAR PAM decreases both deactivation and desensitization together to enhance and prolong synaptic currents.
Related Record Type Details
ACTIVE MOIETY